Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
The Journal of Toxicological Sciences|January 31, 2024
Valproic acid elevates HIF-1α-mediated CGB expression and suppresses glucose uptake in BeWo cellsGo Kitahara, Kazuma Higashisaka, Yurina Nakamoto, et al.Ecotoxicology and Environmental Safety|September 11, 2025
Vacuum ultraviolet-induced degradation of polyethylene and polyvinyl chloride micro/nanoplastics enhances their cytotoxicity and lipid peroxidation levelSota Manabe, Yuya Haga, Hirofumi Tsujino, et al.Scientific Reports|March 18, 2020
Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cellsYing Lin, Kazuma Higashisaka, Takuya Shintani, et al.Nanotoxicology|January 3, 2023
Silver nanoparticles suppress forskolin-induced syncytialization in BeWo cellsYuji Sakahashi, Kazuma Higashisaka, Ryo Isaka, et al.Biological & Pharmaceutical Bulletin|March 30, 2025
Curcumin Is Primarily Distributed in Lung, Spleen and Liver, Metabolized to Glucuronide and Sulfate, and Excreted through Bile and Urine by Using an Amorphous Curcumin Formulation with High AbsorbabilityTomohiro Nakao, Michiko Nakamura, Kazuya Nagano, et al.Journal of Pharmaceutical Sciences|February 2, 2022
Subvisible Particles Derived by Dropping Stress Enhance Anti-PEG Antibody Production and Clearance of PEGylated Proteins in MiceTakaki Nakajima, Kazuya Nagano, Yuka Fukuda, et al.Cancer Research|May 4, 2021
Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase InhibitorsYuya Haga, Ilaria Marrocco, Ashish Noronha, et al.Cell Reports. Medicine|August 9, 2023
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximabIlaria Marrocco, Suvendu Giri, Arturo Simoni-Nieves, et al.Cell Reports. Medicine|August 31, 2024
A bispecific antibody targeting EGFR and AXL delays resistance to osimertinibArturo Simoni-Nieves, Moshit Lindzen, Suvendu Giri, et al.Science Signaling|June 23, 2021
TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasisMary L Uribe, Maik Dahlhoff, Rajbir N Batra, et al.Pageof 4